← Back to Screener
Exact Sciences Corp (EXAS)
Price$104.91
Favorite Metrics
Price vs S&P 500 (26W)98.22%
Price vs S&P 500 (4W)6.43%
Market Capitalization$20.03B
All Metrics
P/CF (Annual)40.75x
Book Value / Share (Quarterly)$12.58
P/TBV (Annual)13.02x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)15.92%
Cash Flow / Share (Quarterly)$1.48
Price vs S&P 500 (YTD)8.19%
Gross Margin (TTM)69.69%
Net Profit Margin (TTM)-6.40%
EPS (TTM)$-1.10
10-Day Avg Trading Volume4.06M
EPS Excl Extra (TTM)$-1.10
Revenue Growth (5Y)16.84%
EPS (Annual)$-1.10
ROI (Annual)-4.39%
Gross Margin (Annual)69.69%
Net Profit Margin (5Y Avg)-23.09%
Cash / Share (Quarterly)$5.06
Revenue Growth QoQ (YoY)23.12%
ROA (Last FY)-3.55%
Revenue Growth TTM (YoY)17.69%
EBITD / Share (TTM)$-0.43
ROE (5Y Avg)-19.21%
Operating Margin (TTM)-6.35%
Cash Flow / Share (Annual)$1.48
P/B Ratio8.34x
P/B Ratio (Quarterly)8.03x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.59x
Net Interest Coverage (TTM)-15.18x
ROA (TTM)-3.57%
EPS Incl Extra (Annual)$-1.10
Current Ratio (Annual)2.43x
Quick Ratio (Quarterly)1.97x
3-Month Avg Trading Volume4.50M
52-Week Price Return136.92%
EV / Free Cash Flow (Annual)75.98x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.76
P/S Ratio (Annual)6.17x
Asset Turnover (Annual)0.55x
52-Week High$104.98
Operating Margin (5Y Avg)-25.81%
EPS Excl Extra (Annual)$-1.10
CapEx CAGR (5Y)-15.13%
Tangible BV CAGR (5Y)1.30%
26-Week Price Return96.35%
Quick Ratio (Annual)1.97x
13-Week Price Return3.10%
Total Debt / Equity (Annual)0.97x
Current Ratio (Quarterly)2.43x
Enterprise Value$21,409.363
Revenue / Share Growth (5Y)11.76%
Asset Turnover (TTM)0.56x
Book Value / Share Growth (5Y)-2.15%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)5.99x
Pretax Margin (Annual)-6.28%
Cash / Share (Annual)$5.06
3-Month Return Std Dev3.30%
Gross Margin (5Y Avg)71.24%
Net Income / Employee (TTM)$-0
ROE (Last FY)-8.66%
Net Interest Coverage (Annual)-23.91x
EPS Basic Excl Extra (Annual)$-1.10
P/FCF (TTM)70.98x
Receivables Turnover (TTM)11.86x
EV / Free Cash Flow (TTM)75.98x
Total Debt / Equity (Quarterly)0.97x
EPS Incl Extra (TTM)$-1.10
Receivables Turnover (Annual)11.86x
ROI (TTM)-4.35%
P/S Ratio (TTM)6.17x
Pretax Margin (5Y Avg)-25.99%
Revenue / Share (Annual)$17.21
Tangible BV / Share (Annual)$7.76
Forward P/E582.83x
Price vs S&P 500 (52W)122.23%
Year-to-Date Return3.30%
5-Day Price Return1.02%
EPS Normalized (Annual)$-1.10
ROA (5Y Avg)-8.60%
Net Profit Margin (Annual)-6.40%
Month-to-Date Return1.48%
Cash Flow / Share (TTM)$-0.44
EBITD / Share (Annual)$-0.43
Operating Margin (Annual)-6.35%
LT Debt / Equity (Annual)0.97x
P/CF (TTM)40.75x
ROI (5Y Avg)-10.23%
LT Debt / Equity (Quarterly)0.97x
EPS Basic Excl Extra (TTM)$-1.10
P/TBV (Quarterly)13.02x
P/B Ratio (Annual)8.03x
Inventory Turnover (TTM)5.99x
Pretax Margin (TTM)-6.28%
Book Value / Share (Annual)$12.58
Price vs S&P 500 (13W)7.56%
Beta0.02x
P/FCF (Annual)71.07x
Revenue / Share (TTM)$17.11
ROE (TTM)-8.51%
52-Week Low$38.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.41
3.34
3.34
3.34
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
CSTLCastle Biosciences, Inc. Common Stock | 47.31x | 3.66% | -12.44% | -5.27% | $25.16 |
About
Exact Sciences develops cancer screening and diagnostic tests for the United States and international markets. Its primary offerings include Cologuard, a noninvasive stool-based DNA test for colorectal cancer screening, and Oncotype DX, a precision oncology suite providing tissue-based genomic testing for cancer risk assessment and treatment guidance. The company is expanding its portfolio with OncoExTra, a liquid-based genomic profiling test, and a pipeline of blood-based solutions for cancer detection and molecular residual disease monitoring.